SCHEMBL4494083

SCHEMBL4494083

O=C(Nc1ccc(F)cc1F)c1cccnc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.59
KDM4E B2RXH2 2/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
RXFP1 Q9HBX9 2/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 1/20 0.54
TAS1R3 Q7RTX0 1/20 0.52
TAS1R1 Q7RTX1 1/20 0.52
TAS1R2 Q8TE23 1/20 0.52
KLK7 P49862 1/20 0.51
P2RY1 P47900 1/20 0.51
GRM4 Q14833 1/20 0.51
RAB9A P51151 2/20 0.50
HTT P42858 2/20 0.50
NPC1 O15118 1/20 0.50
MET P08581 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28683901 0.87 MAPT (0.58) MAPTKDM4EMEN1KMT2ACYP1A2
SCHEMBL4498897 0.86 LMNA (0.53) MAPTKDM4EMEN1KMT2ACYP1A2
SCHEMBL29395986 0.86 MAPT (0.56) MAPTKDM4EMEN1KMT2ACYP1A2
SCHEMBL4493780 0.86 MAPT (0.56) MAPTKDM4EMEN1KMT2ACYP1A2
SCHEMBL32670789 0.86 MAPT (0.56) MAPTKDM4EMEN1KMT2ACYP1A2
Cyclohexane SCHEMBL28734369 0.83 MAPT (0.57) MAPTKDM4EMEN1KMT2ACYP1A2
SCHEMBL27747156 0.83 GRM5 (0.47) MAPTKDM4EMEN1KMT2ACYP1A2
SCHEMBL30599567 0.80 MAPT (0.71) MAPTKDM4EMEN1KMT2ATP53
SCHEMBL10415432 0.79 GRM4 (0.63) MAPTPOLBGRM4RAB9AHTT
SCHEMBL10970533 0.79 KMT2A (0.81) MAPTKDM4EMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937682-B1 MET KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078140-A1 MET kinase inhibitors MET, ABL1, ERBB2 MAPT 3276/4885KDM4E 592/4885MEN1 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.